Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Autor: Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, de Vente, J, De Wit, S, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girard, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Huhn, G, Iribarren, JA, Jain, M, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Orkin, C, Osiyemi, O, Perez-Valero, I, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Prelutsky, D, Pulido, F, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Gil, I Santos, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Wijngaerden, E, Vandekerckhove, L, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y, Orkin, Chloe, Molina, Jean-Michel, Negredo, Eugenia, Arribas, José R, Gathe, Joseph, Eron, Joseph J, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Petrovic, Romana, Vanveggel, Simon, Opsomer, Magda

Publikováno v: In The Lancet HIV January 2018 5(1):e23-e34

Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.

Autor: De Wit S; CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium., Bonnet F; CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, and Bordeaux University, INSERM U1219, Bordeaux Population Health, Bordeaux, France., Osiyemi O; Triple O Research Institute PA, West Palm Beach, FL, USA., Bisshop F; Holdsworth House Medical Brisbane, Queensland, Australia., Olalla J; Unidad de Medicina Interna, Hospital Costa del Sol, Marbella, Spain., Routy JP; McGill University Health Centre, Montréal, QC, Canada., Wyen C; Praxis am Ebertplatz, Cologne, Germany., Moodley R; ViiV Healthcare, Brentford, UK., Pappa K; ViiV Healthcare, Durham, NC, USA., Wang R; ViiV Healthcare, Durham, NC, USA., Oyee J; GSK, Brentford, UK., Saggu P; GSK, Brentford, UK., Letang E; ViiV Healthcare, Madrid, Spain., Wynne B; ViiV Healthcare, Durham, NC, USA., Jones B; ViiV Healthcare, Brentford, UK., Smith KY; ViiV Healthcare, Durham, NC, USA., Ait-Khaled M; ViiV Healthcare, Brentford, UK.

Publikováno v: Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2024 Mar 01. Date of Electronic Publication: 2024 Mar 01.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.

Autor: Ramgopal MN; Midway Immunology and Research Center, Fort Pierce, FL, USA., Castagna A; Vita-Salute San Raffaele University Scientific Institute, Milan, Italy., Cazanave C; Department of Infectious Diseases, Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France., Diaz-Brito V; Department of Infectious Diseases, Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Spain., Dretler R; Infectious Disease Specialists of Atlanta, Decatur, GA, USA., Oka S; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan., Osiyemi O; Triple O Research Institute PA, West Palm Beach, FL, USA., Walmsley S; University Health Network, Toronto, ON, Canada., Sims J; St Hope Foundation, Houston, TX, USA., Di Perri G; Department of Medical Sciences, Unit of Infectious Diseases, University of Turin, Turin, Italy., Sutton K; ViiV Healthcare, Durham, NC, USA., Sutherland-Phillips D; ViiV Healthcare, Durham, NC, USA., Berni A; GSK, Brentford, UK., Latham CL; ViiV Healthcare, Durham, NC, USA., Zhang F; GSK, Collegeville, PA, USA., D'Amico R; ViiV Healthcare, Durham, NC, USA., Pascual Bernáldez M; ViiV Healthcare, Madrid, Spain., Van Solingen-Ristea R; Janssen Research & Development, Beerse, Belgium., Van Eygen V; Janssen Research & Development, Beerse, Belgium., Patel P; ViiV Healthcare, Durham, NC, USA., Chounta V; ViiV Healthcare, Brentford, UK., Spreen WR; ViiV Healthcare, Durham, NC, USA., Garges HP; ViiV Healthcare, Durham, NC, USA., Smith K; ViiV Healthcare, Durham, NC, USA., van Wyk J; ViiV Healthcare, Brentford, UK. Electronic address: jean.x.andre-van-wyk@viivhealthcare.com.

Publikováno v: The lancet. HIV [Lancet HIV] 2023 Sep; Vol. 10 (9), pp. e566-e577. Date of Electronic Publication: 2023 Aug 08.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.